Y Intercept Hong Kong Ltd Makes New Investment in Amgen Inc. $AMGN

Y Intercept Hong Kong Ltd bought a new stake in Amgen Inc. (NASDAQ:AMGN) during the first quarter, HoldingsChannel.com reports. The institutional investor bought 32,401 shares of the medical research company’s stock, valued at approximately $11,400,000.

A number of other institutional investors also recently made changes to their positions in the business. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its position in shares of Amgen by 59.9% during the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 166,082 shares of the medical research company’s stock worth $58,436,000 after buying an additional 62,190 shares in the last quarter. Elevation Point Wealth Partners LLC raised its holdings in Amgen by 91.9% in the first quarter. Elevation Point Wealth Partners LLC now owns 21,443 shares of the medical research company’s stock valued at $7,545,000 after acquiring an additional 10,271 shares in the last quarter. Platform Technology Partners boosted its stake in Amgen by 7.7% during the 1st quarter. Platform Technology Partners now owns 8,387 shares of the medical research company’s stock valued at $2,951,000 after acquiring an additional 603 shares during the last quarter. Jamison Private Wealth Management Inc. boosted its stake in Amgen by 1.7% during the 1st quarter. Jamison Private Wealth Management Inc. now owns 28,100 shares of the medical research company’s stock valued at $9,887,000 after acquiring an additional 468 shares during the last quarter. Finally, Eagle Bay Advisors LLC grew its holdings in Amgen by 5.3% during the 1st quarter. Eagle Bay Advisors LLC now owns 1,173 shares of the medical research company’s stock worth $413,000 after acquiring an additional 59 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.85% of the company’s stock.

Amgen Price Performance

AMGN opened at $374.15 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The company’s 50-day moving average price is $341.87 and its 200 day moving average price is $347.74. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $391.29. The firm has a market cap of $201.93 billion, a price-to-earnings ratio of 26.04, a price-to-earnings-growth ratio of 3.56 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 22.39 earnings per share for the current year.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: A federal judge blocked Colorado’s attempt to cap the price of Amgen’s Enbrel, removing a potentially precedent-setting state-level pricing threat for one of Amgen’s most important legacy drugs. Article: Judge blocks Colorado’s first-of-its-kind price cap on Amgen’s Enbrel
• Positive Sentiment: Amgen continues to advance its pipeline, with updates on Rocatinlimab in asthma, evolocumab bioavailability, and AMG 133 in obesity, reinforcing the company’s long-term growth story. Article: Amgen’s Rocatinlimab Asthma Trial Reaches Phase 2 Finish Line Article: Amgen Refines Its PCSK9 Franchise with New Evolocumab Bioavailability Study Article: Amgen’s AMG 133 Trial Adds a New Data Point in the Obesity Drug Race
• Positive Sentiment: Analysts at Mizuho highlighted Amgen’s pipeline potential, especially MariTide and olpasiran, and raised their price target, signaling continued Street confidence in the company’s future growth prospects. Article: Mizuho Highlights Amgen (AMGN) Pipeline Potential With MariTide and Olpasiran
• Neutral Sentiment: Roche reported positive late-stage lung cancer data for divarasib versus drugs sold by Amgen and Bristol Myers, which adds competitive pressure in the oncology market but does not change Amgen’s fundamentals by itself. Article: Roche KRAS drug succeeds in head-to-head lung cancer study
• Negative Sentiment: A medical journal retracted a pivotal Tavneos paper, which could add to regulatory scrutiny around the drug and weigh on sentiment toward Amgen’s portfolio. Article: Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Daiwa Securities Group dropped their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $350.00 price target on shares of Amgen in a research report on Wednesday, April 8th. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Piper Sandler reissued an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Finally, Canaccord Genuity Group started coverage on Amgen in a research note on Monday, April 20th. They set a “hold” rating and a $366.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $355.50.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.